Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main business involves providing small molecule drug intermediates and limited raw materials for new drug development projects for well-known pharmaceutical companies globally [2][8]. - The company has a significant focus on fluorinated CDMO services, including specialized fluorinated agents and other fluorination processes [3][8]. - As of the 2024 annual report, overseas revenue accounted for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to shareholders of 103 million yuan, reflecting a substantial increase of 163.24% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Group 3: Market Activity - On February 27, the company's stock price fell by 1.85%, with a trading volume of 140 million yuan and a turnover rate of 6.30%, resulting in a total market capitalization of 4.724 billion yuan [1]. - The stock has seen a net outflow of 15.7573 million yuan from major investors today, with a ranking of 49 out of 52 in its industry, indicating a trend of reduced holdings by major funds over the past three days [5][6]. Group 4: Technical Analysis - The average trading cost of the stock is 38.85 yuan, with the stock price approaching a resistance level of 39.30 yuan, suggesting potential for a price correction if it fails to break through this level [7].
金凯生科跌1.85%，成交额1.40亿元，后市是否有机会？